Home/Filings/4/0001193125-25-314740
4//SEC Filing

HENRY CHRISTIAN O 4

Accession 0001193125-25-314740

CIK 0001631574other

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 9:45 PM ET

Size

20.6 KB

Accession

0001193125-25-314740

Insider Transaction Report

Form 4
Period: 2025-12-08
Transactions
  • Sale

    Ordinary Shares

    2025-12-08$12.75/sh6,445$82,17412,700 total
  • Exercise/Conversion

    Ordinary Shares

    2025-12-08$5.97/sh+42,000$250,74054,700 total
  • Sale

    Ordinary Shares

    2025-12-08$12.75/sh42,000$535,50012,700 total
  • Exercise/Conversion

    Ordinary Shares

    2025-12-08$3.50/sh+15,000$52,50027,700 total
  • Sale

    Ordinary Shares

    2025-12-08$14.07/sh15,000$211,05012,700 total
  • Exercise/Conversion

    Ordinary Shares

    2025-12-08$4.58/sh+30,000$137,55042,700 total
  • Sale

    Ordinary Shares

    2025-12-08$18.02/sh30,000$540,60012,700 total
  • Exercise/Conversion

    Share Option (right to buy)

    2025-12-0842,0000 total
    Exercise: $5.97Exp: 2026-08-16Ordinary Shares (42,000 underlying)
  • Exercise/Conversion

    Share Option (right to buy)

    2025-12-0815,0006,000 total
    Exercise: $3.50Exp: 2027-08-15Ordinary Shares (15,000 underlying)
  • Exercise/Conversion

    Share Option (right to buy)

    2025-12-0830,00015,000 total
    Exercise: $4.58Exp: 2028-08-07Ordinary Shares (30,000 underlying)
Footnotes (4)
  • [F1]The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
  • [F2]These share options are fully vested.
  • [F3]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.00 to $14.14 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  • [F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $18.00 to $18.19 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Documents

1 file

Issuer

Wave Life Sciences Ltd.

CIK 0001631574

Entity typeother

Related Parties

1
  • filerCIK 0001263805

Filing Metadata

Form type
4
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 9:45 PM ET
Size
20.6 KB